Stay updated on Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page history shows a new Revision: v3.3.2 replacing v3.3.1. No substantive changes to the study record or visible content are shown.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.1 on the page footer.SummaryDifference0.0%

- Check29 days agoChange DetectedThe funding/operating status notice was removed from the page; the rest of the record history and trial details remain unchanged.SummaryDifference0.3%

- Check43 days agoChange DetectedThe Record History page displays a redesigned layout and updated styling for the version list, while the underlying version data remains unchanged.SummaryDifference0.0%

- Check71 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference8%

- Check79 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page.